AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31440823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron (Arm-A: ondansetron 8 mg days 1-5 with aprepitant day 1: 125 mg, days 2-5: 80 mg)
Number of subjects: 136
Study 31440823 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone (Arm-B)
Number of subjects: 136
Study 31440823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron (Arm-A)
Number of subjects: 136
Study 30905236 — intervention group
Group type: EXPERIMENTAL
Intervention: PUBS
Number of subjects: 64
Study 30905236 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 28420661 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, person-centred transition programme
Number of subjects: 189
Study 28420661 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (standard care)
Number of subjects: 189
Study 28420661 — intervention group
Group type: COMPARATOR
Intervention: Intervention-naïve control group
Number of subjects: 189
Study 25925990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (40mg/m²)
Number of subjects: 496
Study 25925990 — intervention group
Group type: COMPARATOR
Intervention: Control (Paclitaxel 175mg/m² or Doxorubicin 60mg/m²)
Number of subjects: 496
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Number of subjects: 0
Study 22862847 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 0
Study 22862847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21417952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU once daily)
Number of subjects: 3764
Study 21417952 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU twice daily)
Number of subjects: 3764
Study 19877975 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 122
Study 19877975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLON)
Number of subjects: 122
Study 19877975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MPH and CLON
Number of subjects: 122
Study 19877975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 12787857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 13
Study 9989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol group (4 capsules daily, each containing 35 mg tocotrienols and 20 mg alpha-tocopherol)
Number of subjects: 20
Study 9989682 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (4 capsules daily, each providing 20 mg alpha-tocopherol)
Number of subjects: 20
Study 7578498 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 209
Study 7578498 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Control)
Number of subjects: 209
Study 2183733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 6965333 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 96
Study 6965333 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 96
Study 6965333 — intervention group
Group type: COMPARATOR
Intervention: Patients who underwent surgery after medical therapy failed
Number of subjects: 96
Study 31468659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg
Number of subjects: 7226
Study 31468659 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 7226
Study 31731726 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks biweekly in-season weightlifting training
Number of subjects: 20
Study 31731726 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard training program)
Number of subjects: 20
Study 28726232 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day for three months
Number of subjects: 28
Study 26484767 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Bimatoprost 0.01%
Number of subjects: 0
Study 26484767 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% bid
Number of subjects: 0
Study 23175769 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination in HIV-1-infected individuals
Number of subjects: 603
Study 23175769 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccination in HIV-1-uninfected individuals
Number of subjects: 603
Study 23175769 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with standard HBV vaccine series in HIV-1-infected initial nonresponders
Number of subjects: 603
Study 23175769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response including revaccination in HIV-1-infected individuals
Number of subjects: 603
Study 23175769 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of nonresponse to initial vaccination in HIV-1-infected individuals
Number of subjects: 603
Study 23175769 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of nonresponse to revaccination in HIV-1-infected individuals
Number of subjects: 603
Study 21293987 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy until cessation of breastfeeding
Number of subjects: 100
Study 21293987 — intervention group
Group type: COMPARATOR
Intervention: Short course zidovudine monotherapy
Number of subjects: 100
Study 19709317 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-guided decision aid
Number of subjects: 395
Study 19709317 — intervention group
Group type: COMPARATOR
Intervention: Booklet decision aid
Number of subjects: 395
Study 17943989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 24 weeks (Group A)
Number of subjects: 358
Study 17943989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 36 weeks (Group B)
Number of subjects: 358
Study 17943989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 48 weeks (Group C)
Number of subjects: 358
Study 17943989 — intervention group
Group type: COMPARATOR
Intervention: Control group: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks
Number of subjects: 358
Study 14764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 25 mg/wk
Number of subjects: 54
Study 14764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 50 mg/wk
Number of subjects: 54
Study 14764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 125 mg/wk
Number of subjects: 54
Study 14764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg/wk
Number of subjects: 54
Study 14764787 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 600 mg/wk
Number of subjects: 54
Study 11727452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 0
Study 11727452 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10096817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial challenge with HDM extract
Number of subjects: 20
Study 10096817 — intervention group
Group type: COMPARATOR
Intervention: Negative skin responders
Number of subjects: 20
Study 8089246 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse and gum care dentifrice (positive control)
Number of subjects: 208
Study 8089246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% chlorhexidine and 0.34% Zn2+ dentifrice (experimental group)
Number of subjects: 208
Study 8089246 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse and gum care dentifrice (control)
Number of subjects: 208
Study 29453496 — intervention group
Group type: COMPARATOR
Intervention: silorane specific self‐etching adhesive (P90 self‐etch primer and bond) + silorane‐based composite resin (Filtek™ P90 low shrink posterior restorative)
Number of subjects: 26
Study 29453496 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + silorane specific self‐etching adhesive + silorane‐based composite resin
Number of subjects: 26
Study 29453496 — intervention group
Group type: EXPERIMENTAL
Intervention: blasting with aluminum oxide + silorane specific self‐etching adhesive + silorane‐based composite resin
Number of subjects: 26
Study 29453496 — intervention group
Group type: COMPARATOR
Intervention: self‐etching adhesive (Adper™ SE Plus self‐etch adhesive) + dimethacrylate‐based composite resin (Filtek™ P60 posterior restorative)
Number of subjects: 26
Study 27461663 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRS (Intensity Modulated Radiosurgery)
Number of subjects: 45
Study 24385182 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Number of subjects: 1493
Study 24385182 — intervention group
Group type: COMPARATOR
Intervention: UMEC 125 mcg
Number of subjects: 1493
Study 24385182 — intervention group
Group type: COMPARATOR
Intervention: VI 25 mcg
Number of subjects: 1493
Study 24385182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 23089217 — intervention group
Group type: EXPERIMENTAL
Intervention: Organopathic medicines (OM)
Number of subjects: 220
Study 23089217 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutional medicines (CM)
Number of subjects: 220
Study 23089217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined homeopathic treatment (BCOM)
Number of subjects: 220
Study 23089217 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study 20008859 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 159
Study 20008859 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 159
Study 20008859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 159
Study 20008859 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 159
Study 19047814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation and tapered topical steroid
Number of subjects: 26
Study 16886935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and craniocervical training programme
Number of subjects: 81
Study 16886935 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 81
Study 15257494 — intervention group
Group type: COMPARATOR
Intervention: Cartilage guide for columella-prosthesis anchoring
Number of subjects: 22
Study 11761411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (Medtronic 7250 Jewel AF)
Number of subjects: 144
Study 9403918 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered therapy
Number of subjects: 40
Study 9403918 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered therapy with additional behavioral exposure treatment
Number of subjects: 40
Study 9403918 — intervention group
Group type: COMPARATOR
Intervention: Client-centered therapy and behavioral exposure treatment
Number of subjects: 40
Study 8478043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chlorthalidone
Number of subjects: 0
Study 2888252 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 42
Study 2888252 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 42
Study 29909049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-set (CS) configuration
Number of subjects: 52
Study 29909049 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional-set (TS) configuration
Number of subjects: 52
Study 29909049 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study 27919865 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making facilitated by a decision aid
Number of subjects: 898
Study 27919865 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 898
Study 24311117 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet intervention including 300g of vegetables and 25ml of plant oil rich in polyunsaturated fatty acids (PUFA) per day for 8 weeks
Number of subjects: 97
Study 24311117 — intervention group
Group type: COMPARATOR
Intervention: Information only group (control)
Number of subjects: 97
Study 23099060 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnosine (2 g/day)
Number of subjects: 75
Study 23099060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 20070756 — intervention group
Group type: EXPERIMENTAL
Intervention: Osstem SSII Implant system
Number of subjects: 56
Study 20070756 — intervention group
Group type: COMPARATOR
Intervention: Standard Straumann Dental Implant System
Number of subjects: 56
Study 19216237 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-quantitative design including pre and post phases
Number of subjects: 0
Study 15657220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacological stress echocardiography (n = 132)
Number of subjects: 262
Study 15657220 — intervention group
Group type: COMPARATOR
Intervention: Conventional pre-discharge maximum symptom limited exercise ECG (n = 130)
Number of subjects: 262
Study 15657220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacological stress echocardiography
Number of subjects: 262
Study 15657220 — intervention group
Group type: COMPARATOR
Intervention: Conventional pre-discharge maximum symptom limited exercise ECG
Number of subjects: 262
Study 12576736 — intervention group
Group type: COMPARATOR
Intervention: Fresh air filtration system
Number of subjects: 0
Study 12576736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10682201 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy training
Number of subjects: 0
Study 10682201 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing an analogy from two cases
Number of subjects: 0
Study 9084336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine administration method 1
Number of subjects: 44
Study 9084336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine administration method 2
Number of subjects: 44
Study 9084336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 1831083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 34826 400 mg
Number of subjects: 8
Study 1831083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 34826 800 mg
Number of subjects: 8
Study 1831083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 34826 1600 mg
Number of subjects: 8
Study 1831083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7066289 — intervention group
Group type: EXPERIMENTAL
Intervention: High P:S diet (P:S value of 2.0)
Number of subjects: 20
Study 31982831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 20
Study 31982831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 30586691 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency RDN of the main renal arteries
Number of subjects: 120
Study 30586691 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency RDN of the main renal arteries, side branches, and accessories
Number of subjects: 120
Study 30586691 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound-based RDN of the main renal artery
Number of subjects: 120
Study 30586691 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 120
Study 28138788 — intervention group
Group type: EXPERIMENTAL
Intervention: iBGStar™ + DMApp (experimental meter + telemedicine system)
Number of subjects: 182
Study 28138788 — intervention group
Group type: COMPARATOR
Intervention: Traditional glucose meter (Control)
Number of subjects: 182
Study 28138788 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant subjects in iBGStar
Number of subjects: 182
Study 28138788 — intervention group
Group type: COMPARATOR
Intervention: Compliant subjects in Control
Number of subjects: 182
Study 28138788 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine users in iBGStar
Number of subjects: 182
Study 26272719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of 2% prilocaine (60 mg)
Number of subjects: 140
Study 26272719 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of 0.4% plain ropivacaine (12 mg)
Number of subjects: 140
Study 26272719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 24300244 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 72
Study 24300244 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 72
Study 24300244 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 72
Study 22951347 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System menthol cigarette (EHCSS‐K6(M); 5mg tar and 0.3mg nicotine)
Number of subjects: 102
Study 22951347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lark One menthol cigarette (Lark1(M); 1mg tar and 0.1mg nicotine)
Number of subjects: 102
Study 22951347 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 102
Study 22951347 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC16
Number of subjects: 102
Study 19205780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of beta-glucan
Number of subjects: 17
Study 19205780 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan content (0, 2.5, 5, 7.5, and 10 g)
Number of subjects: 17
Study 17489898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of fecal occult blood test (FOBT) for colorectal cancer screening
Number of subjects: 5978
Study 17489898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of mammogram for breast cancer screening (female patients only)
Number of subjects: 5978
Study 17489898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of prostate-specific antigen test (PSA) for prostate cancer screening (male patients only)
Number of subjects: 5978
Study 15590253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal fiberoptic intubation
Number of subjects: 40
Study 15590253 — intervention group
Group type: COMPARATOR
Intervention: Oral fiberoptic intubation
Number of subjects: 40
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Number of subjects: 2763
Study 11755552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes on treatment (insulin)
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes on treatment (oral medications)
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor health
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal itching
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dryness
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge incontinence
Number of subjects: 2763
Study 11755552 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous urinary tract infections
Number of subjects: 2763
Study 9203680 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparasitic therapy
Number of subjects: 48
Study 7963049 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured medication education
Number of subjects: 60
Study 7963049 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured medication education
Number of subjects: 60
Study 2955117 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 72
Study 2955117 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin
Number of subjects: 72
Study 2955117 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 72
Study 2955117 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 72
Study 2955117 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 31912532 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 33
Study 31912532 — intervention group
Group type: EXPERIMENTAL
Intervention: MN + i-PRF
Number of subjects: 33
Study 30987917 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta 0.5 mg/kg 2-weekly
Number of subjects: 31
Study 30987917 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta 1.0 mg/kg 4-weekly
Number of subjects: 31
Study 30987917 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study 27862727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of type A botulinum toxin (BoNTA)
Number of subjects: 40
Study 27862727 — intervention group
Group type: COMPARATOR
Intervention: Intradermal saline solution injection (Control)
Number of subjects: 40
Study 25698492 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS‐402/AD35.TB‐S
Number of subjects: 26
Study 25698492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24581825 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 29
Study 24581825 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 29
Study 22562298 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR)
Number of subjects: 60
Study 22562298 — intervention group
Group type: COMPARATOR
Intervention: No intervention (without HIPR)
Number of subjects: 60